[{"id":"796304d3-46d7-4eb0-aa64-9c9bbe7b7955","acronym":"Pola-R-ICE","url":"https://clinicaltrials.gov/study/NCT04833114","created_at":"2021-04-06T11:55:24.930Z","updated_at":"2025-02-25T14:15:54.989Z","phase":"Phase 3","brief_title":"Polatuzumab Vedotin Plus Rituximab, Ifosfamide, Carboplatin and Etoposide (Pola-R-ICE) Versus R-ICE Alone in Second Line Treatment of Diffuse Large B-cell Lymphoma (DLBCL)","source_id_and_acronym":"NCT04833114 - Pola-R-ICE","lead_sponsor":"GWT-TUD GmbH","biomarkers":" BCL2 • BCL6","pipe":" | ","alterations":" BCL6 rearrangement • BCL2 rearrangement • CD20 negative","tags":["BCL2 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCL6 rearrangement • BCL2 rearrangement • CD20 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • Rituxan (rituximab) • ifosfamide • etoposide IV • Polivy (polatuzumab vedotin-piiq)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 306","initiation":"Initiation: 04/30/2021","start_date":" 04/30/2021","primary_txt":" Primary completion: 12/31/2026","primary_completion_date":" 12/31/2026","study_txt":" Completion: 12/31/2027","study_completion_date":" 12/31/2027","last_update_posted":"2025-02-18"},{"id":"aa0ea678-0fd7-41d5-9cac-558568133e0c","acronym":"EBVision","url":"https://clinicaltrials.gov/study/NCT04554914","created_at":"2021-01-18T21:46:31.475Z","updated_at":"2025-02-25T15:11:41.557Z","phase":"Phase 2","brief_title":"A Study to Evaluate Tabelecleucel in Participants With Epstein-barr Virus-associated Diseases","source_id_and_acronym":"NCT04554914 - EBVision","lead_sponsor":"Atara Biotherapeutics","biomarkers":" CD20","pipe":" | ","alterations":" CD20 negative","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tab-cel (tabelecleucel)"],"overall_status":"Recruiting","enrollment":" Enrollment 190","initiation":"Initiation: 07/14/2021","start_date":" 07/14/2021","primary_txt":" Primary completion: 06/01/2027","primary_completion_date":" 06/01/2027","study_txt":" Completion: 05/01/2029","study_completion_date":" 05/01/2029","last_update_posted":"2025-02-13"},{"id":"28c2e848-0f11-4013-9ceb-12f7e4e707d8","acronym":"ZUMA-7","url":"https://clinicaltrials.gov/study/NCT03391466","created_at":"2021-01-18T16:44:14.245Z","updated_at":"2024-07-02T16:35:15.970Z","phase":"Phase 3","brief_title":"Study of Effectiveness of Axicabtagene Ciloleucel Compared to Standard of Care Therapy in Patients With Relapsed/Refractory Diffuse Large B Cell Lymphoma","source_id_and_acronym":"NCT03391466 - ZUMA-7","lead_sponsor":"Kite, A Gilead Company","biomarkers":" BCL2 • BCL6","pipe":" | ","alterations":" BCL6 rearrangement • BCL2 rearrangement • CD20 negative","tags":["BCL2 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCL6 rearrangement • BCL2 rearrangement • CD20 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • cytarabine • cyclophosphamide • oxaliplatin • Yescarta (axicabtagene ciloleucel) • fludarabine IV • cyclophosphamide intravenous • methylprednisolone sodium succinate"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 359","initiation":"Initiation: 01/25/2018","start_date":" 01/25/2018","primary_txt":" Primary completion: 03/18/2021","primary_completion_date":" 03/18/2021","study_txt":" Completion: 10/01/2024","study_completion_date":" 10/01/2024","last_update_posted":"2024-03-07"},{"id":"d0063cdd-ab4b-4009-8105-73c4b7241cf5","acronym":"IRB-50836","url":"https://clinicaltrials.gov/study/NCT04088890","created_at":"2021-01-18T20:00:46.615Z","updated_at":"2024-07-02T16:35:15.877Z","phase":"Phase 1","brief_title":"Autologous CD22 CAR T Cells in Adults w/ Recurrent or Refractory B Cell Malignancies","source_id_and_acronym":"NCT04088890 - IRB-50836","lead_sponsor":"Stanford University","biomarkers":" CD22","pipe":" | ","alterations":" CD22 positive • CD22 expression • CD20 negative","tags":["CD22"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD22 positive • CD22 expression • CD20 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • cyclophosphamide intravenous • firicabtagene autoleucel (CRG-022)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 52","initiation":"Initiation: 09/12/2019","start_date":" 09/12/2019","primary_txt":" Primary completion: 12/30/2024","primary_completion_date":" 12/30/2024","study_txt":" Completion: 12/30/2037","study_completion_date":" 12/30/2037","last_update_posted":"2024-03-07"},{"id":"9a1bd20f-9971-453e-a407-90e121f47cfc","acronym":"","url":"https://clinicaltrials.gov/study/NCT04697940","created_at":"2021-01-19T20:49:56.659Z","updated_at":"2024-07-02T16:35:20.405Z","phase":"Phase 1/2","brief_title":"Decitabine-primed Tandem CD19/CD20 CAR T Cells Treatment in r/r B-NHL","source_id_and_acronym":"NCT04697940","lead_sponsor":"Han weidong","biomarkers":" BCL2 • CCND1 • BCL6","pipe":" | ","alterations":" Chr t(11;14) • CCND1 overexpression • BCL6 rearrangement • Chr t(11;14)(q13;q32) • BCL2 rearrangement • CD20 negative","tags":["BCL2 • CCND1 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr t(11;14) • CCND1 overexpression • BCL6 rearrangement • Chr t(11;14)(q13;q32) • BCL2 rearrangement • CD20 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • decitabine • fludarabine IV"],"overall_status":"Recruiting","enrollment":" Enrollment 33","initiation":"Initiation: 12/15/2020","start_date":" 12/15/2020","primary_txt":" Primary completion: 12/30/2024","primary_completion_date":" 12/30/2024","study_txt":" Completion: 12/30/2025","study_completion_date":" 12/30/2025","last_update_posted":"2024-02-07"},{"id":"8b4b85ac-4eb7-4ae3-8f3d-9a949ba6aaaa","acronym":"ALEXANDER","url":"https://clinicaltrials.gov/study/NCT03287817","created_at":"2021-01-18T16:14:33.110Z","updated_at":"2024-07-02T16:35:24.309Z","phase":"Phase 1/2","brief_title":"CD19/22 CAR T Cells (AUTO3) for the Treatment of Diffuse Large B Cell Lymphoma","source_id_and_acronym":"NCT03287817 - ALEXANDER","lead_sponsor":"Autolus Limited","biomarkers":" MYC • BCL2 • BCL6","pipe":" | ","alterations":" MYC expression • BCL6 rearrangement • BCL2 rearrangement • CD20 negative","tags":["MYC • BCL2 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MYC expression • BCL6 rearrangement • BCL2 rearrangement • CD20 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cyclophosphamide • AUTO3"],"overall_status":"Completed","enrollment":" Enrollment 73","initiation":"Initiation: 09/05/2017","start_date":" 09/05/2017","primary_txt":" Primary completion: 12/06/2023","primary_completion_date":" 12/06/2023","study_txt":" Completion: 12/06/2023","study_completion_date":" 12/06/2023","last_update_posted":"2024-01-08"},{"id":"2ec47635-b74f-44b7-8369-7b60baf401db","acronym":"","url":"https://clinicaltrials.gov/study/NCT01193842","created_at":"2021-01-18T04:46:39.937Z","updated_at":"2024-07-02T16:35:28.434Z","phase":"Phase 1/2","brief_title":"Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas","source_id_and_acronym":"NCT01193842","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" MYC • BCL2 • CD20 • BCL6","pipe":" | ","alterations":" MYC rearrangement • BCL6 rearrangement • CD20 negative","tags":["MYC • BCL2 • CD20 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MYC rearrangement • BCL6 rearrangement • CD20 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • vincristine • Zolinza (vorinostat) • Truxima (rituximab-abbs) • Riabni (rituximab-arrx) • Delito (rituximab biosimilar) • GB241 (rituximab biosimilar) • JHL1101 (rituximab biosimilar) • Novex (rituximab biosimilar) • SIBP-02 (rituximab biosimilar) • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 107","initiation":"Initiation: 10/06/2010","start_date":" 10/06/2010","primary_txt":" Primary completion: 11/12/2016","primary_completion_date":" 11/12/2016","study_txt":" Completion: 05/19/2022","study_completion_date":" 05/19/2022","last_update_posted":"2023-11-21"},{"id":"3f4c5428-51b9-428c-8b7e-591df451a815","acronym":"","url":"https://clinicaltrials.gov/study/NCT05768529","created_at":"2023-03-14T14:01:52.026Z","updated_at":"2024-07-02T16:35:36.640Z","phase":"Phase 1/2","brief_title":"Clinical Study of U16 in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma","source_id_and_acronym":"NCT05768529","lead_sponsor":"Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd","biomarkers":" IL6","pipe":" | ","alterations":" CD20 positive • CD20 negative","tags":["IL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive • CD20 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • U16"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 03/28/2023","start_date":" 03/28/2023","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2023-09-21"},{"id":"9ab66824-8e3a-4720-b4ba-ed7f93a0f589","acronym":"PMB-BAFFR-102","url":"https://clinicaltrials.gov/study/NCT05370430","created_at":"2023-09-13T18:45:10.718Z","updated_at":"2024-07-02T16:35:37.370Z","phase":"Phase 1","brief_title":"BAFFR-targeting CAR T Cells for Patients With Relapsed or Refractory B-NHL","source_id_and_acronym":"NCT05370430 - PMB-BAFFR-102","lead_sponsor":"PeproMene Bio, Inc.","biomarkers":" BCL2 • BCL6","pipe":" | ","alterations":" BCL6 rearrangement • BCL2 rearrangement • CD20 negative • TNFRSF13C expression","tags":["BCL2 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCL6 rearrangement • BCL2 rearrangement • CD20 negative • TNFRSF13C expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PMB-CT01"],"overall_status":"Recruiting","enrollment":" Enrollment 36","initiation":"Initiation: 06/13/2022","start_date":" 06/13/2022","primary_txt":" Primary completion: 07/13/2027","primary_completion_date":" 07/13/2027","study_txt":" Completion: 06/13/2028","study_completion_date":" 06/13/2028","last_update_posted":"2023-09-12"},{"id":"d6f43bf5-4e79-4d99-b785-9354c5c58f6c","acronym":"","url":"https://clinicaltrials.gov/study/NCT06014073","created_at":"2023-08-28T14:08:34.962Z","updated_at":"2024-07-02T16:35:37.560Z","phase":"Phase 1/2","brief_title":"TRAC and Power3 Genes Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in r/r B-NHL","source_id_and_acronym":"NCT06014073","lead_sponsor":"Chinese PLA General Hospital","biomarkers":" BCL2 • CCND1 • BCL6 • IL6 • TNFA • IL2 • IL10","pipe":" | ","alterations":" CD19 positive • Chr t(11;14) • CCND1 overexpression • BCL6 rearrangement • Chr t(11;14)(q13;q32) • BCL2 rearrangement • CD20 negative","tags":["BCL2 • CCND1 • BCL6 • IL6 • TNFA • IL2 • IL10"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 positive • Chr t(11;14) • CCND1 overexpression • BCL6 rearrangement • Chr t(11;14)(q13;q32) • BCL2 rearrangement • CD20 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • ET-901"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 09/06/2023","start_date":" 09/06/2023","primary_txt":" Primary completion: 09/01/2025","primary_completion_date":" 09/01/2025","study_txt":" Completion: 09/01/2026","study_completion_date":" 09/01/2026","last_update_posted":"2023-09-11"},{"id":"d5353cd0-2f5f-47ab-aa5b-4def378330e9","acronym":"","url":"https://clinicaltrials.gov/study/NCT05472558","created_at":"2022-07-25T20:54:30.748Z","updated_at":"2024-07-02T16:35:43.057Z","phase":"Phase 1","brief_title":"Clinical Study of Cord Blood-derived CAR-NK Cells Targeting CD19 in the Treatment of Refractory/Relapsed B-cell NHL","source_id_and_acronym":"NCT05472558","lead_sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","biomarkers":" CD19","pipe":" | ","alterations":" CD19 expression • CD20 negative","tags":["CD19"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 expression • CD20 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CB CAR-NK019"],"overall_status":"Recruiting","enrollment":" Enrollment 48","initiation":"Initiation: 09/10/2022","start_date":" 09/10/2022","primary_txt":" Primary completion: 09/10/2023","primary_completion_date":" 09/10/2023","study_txt":" Completion: 09/10/2025","study_completion_date":" 09/10/2025","last_update_posted":"2023-07-13"},{"id":"b2a4ea25-8d18-422a-b5fb-b8838e229814","acronym":"","url":"https://clinicaltrials.gov/study/NCT05631912","created_at":"2022-11-30T17:57:35.016Z","updated_at":"2024-07-02T16:35:43.904Z","phase":"Phase 1/2","brief_title":"TRAC Locus-inserted CD19-targeting STAR-T Cell Therapy in r/r B-NHL","source_id_and_acronym":"NCT05631912","lead_sponsor":"Chinese PLA General Hospital","biomarkers":" BCL2 • CCND1 • BCL6 • IL6 • TNFA • IL2 • IL10","pipe":" | ","alterations":" CD19 positive • Chr t(11;14) • CCND1 overexpression • BCL6 rearrangement • Chr t(11;14)(q13;q32) • BCL2 rearrangement • CD20 negative","tags":["BCL2 • CCND1 • BCL6 • IL6 • TNFA • IL2 • IL10"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 positive • Chr t(11;14) • CCND1 overexpression • BCL6 rearrangement • Chr t(11;14)(q13;q32) • BCL2 rearrangement • CD20 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • autologous TRAC locus-inserted CD19-STAR-T"],"overall_status":"Recruiting","enrollment":" Enrollment 38","initiation":"Initiation: 06/30/2023","start_date":" 06/30/2023","primary_txt":" Primary completion: 12/15/2024","primary_completion_date":" 12/15/2024","study_txt":" Completion: 12/15/2025","study_completion_date":" 12/15/2025","last_update_posted":"2023-07-06"},{"id":"b48e675a-8f57-4222-bd60-102284af62b8","acronym":"","url":"https://clinicaltrials.gov/study/NCT04232826","created_at":"2021-01-18T20:35:26.256Z","updated_at":"2024-07-02T16:35:52.149Z","phase":"Phase 1","brief_title":"A Clinical Trial of CNCT19 Cells in the Treatment of CD19 Positive Relapsed or Refractory Diffuse Non-Hodgkin Lymphoma","source_id_and_acronym":"NCT04232826","lead_sponsor":"Juventas Cell Therapy Ltd.","biomarkers":" PD-L1 • BCL2 • BCL6","pipe":" | ","alterations":" CD19 positive • BCL6 rearrangement • BCL2 rearrangement • CD20 negative","tags":["PD-L1 • BCL2 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 positive • BCL6 rearrangement • BCL2 rearrangement • CD20 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • Yorwida (inaticabtagene autoleucel)"],"overall_status":"Completed","enrollment":" Enrollment 9","initiation":"Initiation: 01/15/2020","start_date":" 01/15/2020","primary_txt":" Primary completion: 01/01/2021","primary_completion_date":" 01/01/2021","study_txt":" Completion: 11/01/2022","study_completion_date":" 11/01/2022","last_update_posted":"2023-03-28"},{"id":"04c84023-9d31-44bc-aeb7-71f2203c82e9","acronym":"","url":"https://clinicaltrials.gov/study/NCT04877080","created_at":"2021-05-07T12:53:17.300Z","updated_at":"2024-07-02T16:35:55.885Z","phase":"Phase 1","brief_title":"CD19 and BCMA Targeted Fast Dual CAR-T for CD19+ Refractory/Relapsed B-NHL","source_id_and_acronym":"NCT04877080","lead_sponsor":"920th Hospital of Joint Logistics Support Force of People's Liberation Army of China","biomarkers":" IL6 • IL2 • IL10","pipe":" | ","alterations":" CD19 positive • CD19 expression • CD20 negative","tags":["IL6 • IL2 • IL10"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 positive • CD19 expression • CD20 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AZD0120"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 05/05/2021","start_date":" 05/05/2021","primary_txt":" Primary completion: 06/30/2023","primary_completion_date":" 06/30/2023","study_txt":" Completion: 12/31/2023","study_completion_date":" 12/31/2023","last_update_posted":"2023-02-10"},{"id":"72825679-0a90-44dd-8f03-cc33bf0d6f85","acronym":"","url":"https://clinicaltrials.gov/study/NCT05667155","created_at":"2022-12-28T16:01:39.436Z","updated_at":"2024-07-02T16:35:56.379Z","phase":"Phase 1","brief_title":"Clinical Study of Cord Blood-derived CAR NK Cells Targeting CD19/CD70 in Refractory/Relapsed B-cell Non-Hodgkin Lymphoma","source_id_and_acronym":"NCT05667155","lead_sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","biomarkers":" CD20 • CD19","pipe":" | ","alterations":" CD19 expression • CD20 negative","tags":["CD20 • CD19"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 expression • CD20 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dualCAR-NK19/70"],"overall_status":"Recruiting","enrollment":" Enrollment 48","initiation":"Initiation: 12/15/2022","start_date":" 12/15/2022","primary_txt":" Primary completion: 01/01/2025","primary_completion_date":" 01/01/2025","study_txt":" Completion: 12/30/2025","study_completion_date":" 12/30/2025","last_update_posted":"2023-02-06"},{"id":"7f7e2c43-583a-4168-9680-7d625fc3f2db","acronym":"","url":"https://clinicaltrials.gov/study/NCT05472610","created_at":"2022-07-25T20:54:31.526Z","updated_at":"2024-07-02T16:36:06.800Z","phase":"Phase 2","brief_title":"Study of Efficacy of BZ019 in Large B-cell Lymphoma","source_id_and_acronym":"NCT05472610","lead_sponsor":"Shanghai Mengchao Cancer Hospital","biomarkers":" IL6 • IL2 • IL10","pipe":" | ","alterations":" CD20 negative","tags":["IL6 • IL2 • IL10"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • BZ019"],"overall_status":"Recruiting","enrollment":" Enrollment 36","initiation":"Initiation: 06/04/2021","start_date":" 06/04/2021","primary_txt":" Primary completion: 01/01/2023","primary_completion_date":" 01/01/2023","study_txt":" Completion: 01/01/2023","study_completion_date":" 01/01/2023","last_update_posted":"2022-07-25"},{"id":"4bbcf32a-6435-4ba3-b131-14dc4e900707","acronym":"","url":"https://clinicaltrials.gov/study/NCT04887012","created_at":"2021-05-14T12:52:39.560Z","updated_at":"2024-07-02T16:36:30.256Z","phase":"Phase 1","brief_title":"Clinical Study of HLA Haploidentical CAR-NK Cells Targeting CD19 in the Treatment of Refractory/Relapsed B-cell NHL","source_id_and_acronym":"NCT04887012","lead_sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","biomarkers":" CD19","pipe":" | ","alterations":" CD19 expression • CD20 negative","tags":["CD19"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 expression • CD20 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CB CAR-NK019"],"overall_status":"Recruiting","enrollment":" Enrollment 25","initiation":"Initiation: 05/01/2021","start_date":" 05/01/2021","primary_txt":" Primary completion: 05/01/2022","primary_completion_date":" 05/01/2022","study_txt":" Completion: 05/01/2024","study_completion_date":" 05/01/2024","last_update_posted":"2021-05-14"},{"id":"e0854a67-8b83-41a5-a3f8-45934f25242c","acronym":"","url":"https://clinicaltrials.gov/study/NCT00536978","created_at":"2021-01-18T01:56:59.877Z","updated_at":"2024-07-02T16:36:40.726Z","phase":"Phase 2","brief_title":"Natural Killer (NK) Cell Adback After Allogeneic Stem Cell Transplant With Campath-IH Plus Chemorx for Patients With Lymphoid Malignancies","source_id_and_acronym":"NCT00536978","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" CD20","pipe":" | ","alterations":" CD20 negative","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • cytarabine • cyclophosphamide • etoposide IV • Campath (alemtuzumab) • carmustine • melphalan • fludarabine IV • Depocyte (liposomal cytarabine) • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 22","initiation":"Initiation: 09/01/2007","start_date":" 09/01/2007","primary_txt":" Primary completion: 11/01/2010","primary_completion_date":" 11/01/2010","study_txt":" Completion: 11/01/2010","study_completion_date":" 11/01/2010","last_update_posted":"2020-09-24"},{"id":"35cdc032-29a6-4e99-a7d5-d2b3f5f5832a","acronym":"","url":"https://clinicaltrials.gov/study/NCT04412174","created_at":"2021-01-18T21:16:18.074Z","updated_at":"2025-02-25T14:59:08.827Z","phase":"Phase 1","brief_title":"A Study of GC022F CAR-T Cell Immunotherapy for Relapsed or Refractory B- NHL","source_id_and_acronym":"NCT04412174","lead_sponsor":"Hebei Yanda Ludaopei Hospital","biomarkers":" CD22","pipe":" | ","alterations":" CD22 positive • CD20 negative","tags":["CD22"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD22 positive • CD20 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e GC022F • S1904"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 06/01/2020","start_date":" 06/01/2020","primary_txt":" Primary completion: 12/01/2022","primary_completion_date":" 12/01/2022","study_txt":" Completion: 12/01/2022","study_completion_date":" 12/01/2022","last_update_posted":"2020-06-02"},{"id":"a0eaad27-66db-41b8-9f54-195922d8ae6e","acronym":"","url":"https://clinicaltrials.gov/study/NCT04067414","created_at":"2021-01-18T19:55:37.509Z","updated_at":"2024-07-02T16:36:48.286Z","phase":"Phase 1","brief_title":"Exploratory Study of CD19-targeted Chimeric Antigen Receptor T Cells(BZ019) for Relapsed and Refractory B-cell Lymphoma","source_id_and_acronym":"NCT04067414","lead_sponsor":"Institute of Hematology \u0026 Blood Diseases Hospital","biomarkers":" BCL2 • BCL6","pipe":" | ","alterations":" BCL6 rearrangement • BCL2 rearrangement • CD20 negative","tags":["BCL2 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCL6 rearrangement • BCL2 rearrangement • CD20 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • BZ019"],"overall_status":"Unknown status","enrollment":" Enrollment 12","initiation":"Initiation: 06/14/2018","start_date":" 06/14/2018","primary_txt":" Primary completion: 07/31/2020","primary_completion_date":" 07/31/2020","study_txt":" Completion: 12/31/2020","study_completion_date":" 12/31/2020","last_update_posted":"2020-03-17"},{"id":"3e123ded-4815-47bf-911a-cf353196647d","acronym":"","url":"https://clinicaltrials.gov/study/NCT04303247","created_at":"2021-01-18T20:52:17.814Z","updated_at":"2025-02-25T14:58:57.173Z","phase":"Phase 1","brief_title":"CD19 and CD22 Dual-targeted CAR-T Cells for Relapsed or Refractory B-NHL","source_id_and_acronym":"NCT04303247","lead_sponsor":"Xinqiao Hospital of Chongqing","biomarkers":" CD19 • CD22","pipe":" | ","alterations":" CD20 negative","tags":["CD19 • CD22"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 05/01/2020","start_date":" 05/01/2020","primary_txt":" Primary completion: 05/01/2021","primary_completion_date":" 05/01/2021","study_txt":" Completion: 05/01/2023","study_completion_date":" 05/01/2023","last_update_posted":"2020-03-11"},{"id":"7f8786d1-59b3-405f-9c9b-cbd9c774d00f","acronym":"","url":"https://clinicaltrials.gov/study/NCT04250324","created_at":"2021-01-18T20:39:15.886Z","updated_at":"2024-07-02T16:36:50.621Z","phase":"Phase 1","brief_title":"Study of Safety and Efficacy of BZ019 in (R/R) Large B-cell Lymphoma","source_id_and_acronym":"NCT04250324","lead_sponsor":"Shanghai Cell Therapy Group Co.,Ltd","biomarkers":" BCL2 • BCL6","pipe":" | ","alterations":" BCL6 rearrangement • BCL2 rearrangement • CD20 negative","tags":["BCL2 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCL6 rearrangement • BCL2 rearrangement • CD20 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • BZ019"],"overall_status":"Recruiting","enrollment":" Enrollment 21","initiation":"Initiation: 11/19/2019","start_date":" 11/19/2019","primary_txt":" Primary completion: 08/01/2022","primary_completion_date":" 08/01/2022","study_txt":" Completion: 12/01/2022","study_completion_date":" 12/01/2022","last_update_posted":"2020-01-31"},{"id":"03b35f16-d501-472b-8e72-f8828b4fc9bc","acronym":"","url":"https://clinicaltrials.gov/study/NCT04011293","created_at":"2021-01-18T19:42:25.117Z","updated_at":"2024-07-02T16:36:58.292Z","phase":"Phase 1","brief_title":"A Clinical Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Injection (CNCT19) in the Treatment of Cluster of Differentiation 19 (CD19) Positive Relapsed or Refractory B Cell Malignancies","source_id_and_acronym":"NCT04011293","lead_sponsor":"Shandong University","biomarkers":" TP53 • CD19","pipe":" | ","alterations":" TP53 mutation • Chr del(17p) • CD19 positive • CD19 expression • CD20 negative","tags":["TP53 • CD19"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • Chr del(17p) • CD19 positive • CD19 expression • CD20 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Yorwida (inaticabtagene autoleucel)"],"overall_status":"Unknown status","enrollment":" Enrollment 20","initiation":"Initiation: 07/01/2019","start_date":" 07/01/2019","primary_txt":" Primary completion: 07/01/2020","primary_completion_date":" 07/01/2020","study_txt":" Completion: 04/01/2022","study_completion_date":" 04/01/2022","last_update_posted":"2019-07-08"},{"id":"b48d6c5d-0279-4bba-90fc-7e2a494b454c","acronym":"SGH652","url":"https://clinicaltrials.gov/study/NCT01226849","created_at":"2021-01-18T04:55:50.756Z","updated_at":"2024-07-02T16:37:22.997Z","phase":"Phase 1","brief_title":"Feasibility Study Of Adding Bortezomib to R-ICE Chemotherapy To Treat Relapsed/ Refractory Diffuse Large B-Cell Lymphoma","source_id_and_acronym":"NCT01226849 - SGH652","lead_sponsor":"Singapore General Hospital","biomarkers":" CD20","pipe":" | ","alterations":" CD20 negative","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • Rituxan (rituximab) • bortezomib • ifosfamide • etoposide IV"],"overall_status":"Completed","enrollment":" Enrollment 6","initiation":"Initiation: 11/01/2010","start_date":" 11/01/2010","primary_txt":" Primary completion: 11/01/2014","primary_completion_date":" 11/01/2014","study_txt":" Completion: 11/01/2014","study_completion_date":" 11/01/2014","last_update_posted":"2017-04-27"}]